Bristol-Myers Squibb – Guerilla Stock Trading https://www.guerillastocktrading.com/tag/bristol-myers-squibb/ Live Free or Die Traying Fri, 26 Jul 2024 20:44:57 +0000 en-US hourly 1 https://wordpress.org/?v=6.6.1 Bristol-Myers Squibb鈥檚 stock soars! With an earnings beat and booming new drug sales, it’s time to pay attention! 馃搱 https://www.guerillastocktrading.com/bristol-myers-squibbs-stock-soars-with-an-earnings-beat-and-booming-new-drug-sales-its-time-to-pay-attention-%f0%9f%93%88/ Fri, 26 Jul 2024 20:44:56 +0000 https://www.guerillastocktrading.com/?p=377284

Earnings and Revenue Beat Expectations On July 26, 2024, Bristol-Myers Squibb (BMY) experienced a notable increase in its…

This article Bristol-Myers Squibb鈥檚 stock soars! With an earnings beat and booming new drug sales, it’s time to pay attention! 馃搱 appeared first on Guerilla Stock Trading.

]]> Exploring the Dynamic Landscape of the Radiopharmaceutical Market https://www.guerillastocktrading.com/exploring-the-dynamic-landscape-of-the-radiopharmaceutical-market/ Sun, 25 Feb 2024 18:10:13 +0000 https://www.guerillastocktrading.com/?p=372252 The global market for radiopharmaceuticals is on a trajectory of significant expansion, poised to reach a substantial valuation…

This article Exploring the Dynamic Landscape of the Radiopharmaceutical Market appeared first on Guerilla Stock Trading.

]]> Bristol-Myers Squibb’s Strategic Move: Acquiring Karuna Therapeutics to Boost Neuroscience Portfolio https://www.guerillastocktrading.com/bristol-myers-squibbs-strategic-move-acquiring-karuna-therapeutics-to-boost-neuroscience-portfolio/ Tue, 26 Dec 2023 21:15:53 +0000 https://www.guerillastocktrading.com/?p=370091 While the broader mergers and acquisitions (M&A) landscape has experienced a slowdown, the pharmaceutical and biotech industries have…

This article Bristol-Myers Squibb’s Strategic Move: Acquiring Karuna Therapeutics to Boost Neuroscience Portfolio appeared first on Guerilla Stock Trading.

]]> Anticipated Surge in Merger and Acquisition Activity in 2024 https://www.guerillastocktrading.com/anticipated-surge-in-merger-and-acquisition-activity-in-2024/ Mon, 25 Dec 2023 01:42:50 +0000 https://www.guerillastocktrading.com/?p=370056 Merger and acquisition (M&A) activity is poised to experience a significant uptick in the upcoming year. Borrowing is…

This article Anticipated Surge in Merger and Acquisition Activity in 2024 appeared first on Guerilla Stock Trading.

]]> Michael Yee’s Positive Outlook for the Biotechnology Sector in 2024 https://www.guerillastocktrading.com/michael-yees-positive-outlook-for-the-biotechnology-sector-in-2024/ Sun, 24 Dec 2023 01:45:19 +0000 https://www.guerillastocktrading.com/?p=370012 In a recent interview on CNBC, Michael Yee, a Senior Biotech Analyst at Jefferies, shared his insights into…

This article Michael Yee’s Positive Outlook for the Biotechnology Sector in 2024 appeared first on Guerilla Stock Trading.

]]> Bristol-Myers Squibb’s Bold Move: Acquiring Karuna Therapeutics for $14 Billion https://www.guerillastocktrading.com/bristol-myers-squibbs-bold-move-acquiring-karuna-therapeutics-for-14-billion/ Fri, 22 Dec 2023 21:34:54 +0000 https://www.guerillastocktrading.com/?p=369954 Amidst a relatively sluggish M&A landscape, the pharmaceutical and biotech sectors have emerged as hotbeds of deal-making activity.…

This article Bristol-Myers Squibb’s Bold Move: Acquiring Karuna Therapeutics for $14 Billion appeared first on Guerilla Stock Trading.

]]> Bristol-Myers Squibb: A Compelling Opportunity for Long-Term Investors https://www.guerillastocktrading.com/bristol-myers-squibb-a-compelling-opportunity-for-long-term-investors/ Sat, 02 Dec 2023 22:26:38 +0000 https://www.guerillastocktrading.com/?p=368870

In the ever-evolving landscape of the pharmaceutical industry, Bristol-Myers Squibb (BMY) has been on a rollercoaster ride over…

This article Bristol-Myers Squibb: A Compelling Opportunity for Long-Term Investors appeared first on Guerilla Stock Trading.

]]> Bristol-Myers Faces Setbacks as FDA Delays Abecma Decision and Bayer Halts Cardiovascular Drug Trial https://www.guerillastocktrading.com/bristol-myers-faces-setbacks-as-fda-delays-abecma-decision-and-bayer-halts-cardiovascular-drug-trial/ Mon, 20 Nov 2023 21:16:44 +0000 https://www.guerillastocktrading.com/?p=368450 Bristol-Myers Squibb (BMY) recently found itself in a challenging position, receiving a double blow of adverse news. First,…

This article Bristol-Myers Faces Setbacks as FDA Delays Abecma Decision and Bayer Halts Cardiovascular Drug Trial appeared first on Guerilla Stock Trading.

]]>